Blog / Archives
Rayno Life Science: Biotechnology Sector Should Find Support Today
Trends from early trading show promise for intermediate support in larger cap biotech shares today with the NASDAQ up 0.5% in early trading. This could be a good day for covering shorts and...
Macro Rules: With Election Over Focus Reverts to Fiscal Cliff and Europe
Draghi Comments Trigger Sell-Off of 2% with Bottom Holding-Euro Down, Bonds Up Mario Draghi sparked the current 2012 rally in July saying he would support the Euro no matter what. Today reality set...
Rayno Life Sciences-DX, Devices and Tools: CSII Revenues Up 25%
CSII ($12.17) stock is up 4.2% on sales growth in treatment of Peripheral Artery Disease (PAD) Cardiovascular Systems revenues were up 25% over Fiscal Q1 2012 to $23.3M . The Q1 2013 loss was $5,2M...
Sell-Off Continues in Biotechnology Sector: Down 2% With High Fliers Down More
Huge Profits YTD Bring Selling-Momentum is Broken Profit taking has hit the biotechnology sector again today with major ETFs down 2% and momentum stocks hit harder. We recommended caution on 10/22...
Cepheid (CPHD $31.40)-Good Entry Point For Long Term
Cepheid in Low $30's- Long Term Buy Cepheid is not a cheap stock with a Price to Sales of 6.82, market cap of $2.10B and a forward PE of 122.58 but we see a capitulation of sellers who were playing...
NASDAQ Correction Hits Biotechnology Stocks: Update 1 10/24
Biotech At Risk: Take a Little Off Speculative Stocks Biotechnology remains one of the strongest sectors of 2012 especially earnings driven, large cap stocks all doing well today: Amgen (AMGN $88.4)...
Rayno Life Sciences: Investor Election Guide from Credit Suisse
Ultimate Presidential Election Guide Click above for an interesting sector and stock review from Credit Suisse including major positions of candidates. Stocks in the Rayno Life Sciences Portfolio...
Will The Biotechnology Bull Market Stimulate Venture Investing?
Notes from the BioInvestor Forum October 9-12--Biotech Investing The BioInvestor Forum held every year at this time in San Francisco is one of the premier events for emerging companies. Over 500...
Rayno Life Science DX and Tools Update: EXAS
Exact Sciences (EXAS) is down about 8% to $10.65 on heavy volume after a Wedbush Downgrade to Neutral. Preliminary data coming next week. The stock was added to the Rayno Life Sciences Portfolio on...
Rayno Life Science Portfolios: Biotechnology Stocks Should Outperform in Q4
Good Day for Biotech with a Strong Appetite for Two IPOs in A Choppy Market Intercept Pharmaceuticals (ICPT) was up 29.33% to $19.40 on a public offering of 5M shares at $15 raising $75M. The...